Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yishen Qingdu Granules
- Development stage
- Phase 3
- Lead developer
- Jilin Institute of Pharmaceutical Research
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Yishen Qingdu Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Jilin Institute of Pharmaceutical Research for the treatment of chronic kidney disease (CKD) and chronic renal failure. The preparation is formulated based on TCM principles aimed at tonifying the kidney, activating blood circulation, and clearing dampness and toxins. It typically consists of a complex mixture of herbal extracts, including *Astragalus membranaceus* (Huangqi), *Rheum palmatum* (Dahuang), *Salvia miltiorrhiza* (Danshen), and *Poria cocos* (Fuling). Mechanistically, the drug is designed to improve renal function by reducing serum creatinine and blood urea nitrogen levels, decreasing proteinuria, and inhibiting renal interstitial fibrosis. Research suggests it acts by modulating the TGF-β1/Smad signaling pathway and suppressing pro-inflammatory mediators such as TNF-α and IL-6, thereby slowing the progression of renal damage.
- Brand names
- Yishen Qingdu Granules
- Other names
- Yishen Qingdu KeliYi Shen Qing Du Ke Li
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)IL-6 (Interleukin 6)RELA (Nuclear Factor Kappa B Subunit p65)TNFA (Tumor necrosis factor alpha (soluble))TP53 (Cellular Tumor Antigen p53 R175H)TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on Yishen Qingdu Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yishen Qingdu Granules.